EXAGEN INC (XGN) Stock Price, Quote, News and Overview
NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD
XGN Quote, Performance and Key Statistics
EXAGEN INC
NASDAQ:XGN (2/11/2025, 9:46:55 AM)
4.84
+0.04 (+0.83%)
The current stock price of XGN is 4.84 USD. In the past month the price increased by 51.42%. In the past year, price increased by 124.3%.
XGN Latest News and Analysis
Tuesday's session: top gainers and losers
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management...
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing...
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
XGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.65 | 333.57B | ||
| AMGN | AMGEN INC | 14.62 | 155.72B | ||
| GILD | GILEAD SCIENCES INC | 21.56 | 119.03B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1586.21 | 118.46B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.78 | 74.15B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.84B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.38B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.88B | ||
| NTRA | NATERA INC | N/A | 22.64B | ||
| BIIB | BIOGEN INC | 8.59 | 20.45B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.58 | 15.83B |
Related stock screener links
About XGN
Company Profile
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 174 full-time employees. The company went IPO on 2019-09-19. The firm has developed and is commercializing a portfolio of testing products, under its AVISE brand. The company commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Company Info
EXAGEN INC
1261 Liberty Way
Vista CALIFORNIA 92081 US
CEO: Fortunato Ron Rocca
Employees: 177
Company Website: https://exagen.com/
Investor Relations: http://investors.exagen.com
Phone: 17605601501
XGN FAQ
What is the stock price of XGN?
The current stock price of XGN is 4.84 USD.
What is the symbol for EXAGEN INC stock?
The exchange symbol of EXAGEN INC is XGN and it is listed on the Nasdaq exchange.
On which exchange is XGN stock listed?
XGN stock is listed on the Nasdaq exchange.
Is XGN a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for XGN, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of XGN.
Does XGN stock pay dividends?
XGN does not pay a dividend.
What is the Price/Earnings (PE) ratio of XGN?
XGN does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
What is the Short Interest ratio of XGN stock?
The outstanding short interest for XGN is 0.08% of its float.
XGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to XGN. When comparing the yearly performance of all stocks, XGN is one of the better performing stocks in the market, outperforming 96.6% of all stocks.
XGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XGN. Both the profitability and financial health of XGN have multiple concerns.
XGN Financial Highlights
Over the last trailing twelve months XGN reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 49.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.82% | ||
| ROE | -131.54% | ||
| Debt/Equity | 1.54 |
XGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to XGN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 32.79% and a revenue growth 10.79% for XGN